Across TCGA pan-cancer cohorts, PLA2G6 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PLA2G6 data layer compared with 26 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLA2G6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLA2G6 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where PLA2G6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.215	0.546	.017	6	view →
HNSC	DFS	Quartile	III,IV	0.833	0.461	.036	4	view →
LUAD	DFS	Tertile	All	0.355	0.904	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PLA2G6 tumor-vs-normal RNA expression · all PLA2G6 data types